艾伯维公司 ABBV 深沪

等待开盘 03-27 09:30:00 美东时间

211.10

+3.840

+1.85%

华盛通

立即下载

最高237.11
今开207.45
成交量 357.31万股
最低 201.80
昨收 207.26
总市值 3.73亿
52周最高 244.49
市盈率 ^静 32.71
换手率 202.21%
52周最低 164.39
委比 68.93%
总股本 0.02亿
历史最高 244.49
量比 0.66
振幅 17.04%
历史最低 1.78
每手 1
风险率

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie beat Q4 earnings and sales estimates, driven by strong Skyrizi and Rinvoq growth. The drugmaker raised its 2026 outlook despite falling Humira sales and mixed results in aesthetics.

02-05 01:38
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs

UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.

01-29 01:07
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.

01-28 18:51
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.

01-26 19:01
10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. ...

01-16 01:35
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.

01-13 21:09
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.

01-12 18:47
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports

01-09 02:41
AbbVie Says 'Not In Discussions With Revolution Medicines'

- Reuters

01-08 05:02
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.

01-06 00:59

派息除权日	每股总股息	派息日期
2022-04-13	1.41	2022-05-16
2022-01-13	1.41	2022-02-15
2021-10-14	1.30	2021-11-15
2021-07-14	1.30	2021-08-16
2021-04-14	1.30	2021-05-14
2021-01-14	1.30	2021-02-16
2020-10-14	1.18	2020-11-16
2020-07-14	1.18	2020-08-14
2020-04-14	1.18	2020-05-15
2020-01-14	1.18	2020-02-14
2019-10-11	1.07	2019-11-15
2019-07-12	1.07	2019-08-15
2019-04-12	1.07	2019-05-15
2019-01-14	1.07	2019-02-15
2018-10-12	0.96	2018-11-15
2018-07-12	0.96	2018-08-15
2018-04-12	0.96	2018-05-15
2018-01-11	0.71	2018-02-15
2017-10-12	0.64	2017-11-15
2017-07-12	0.64	2017-08-15
2017-04-11	0.64	2017-05-15
2017-01-11	0.64	2017-02-15
2016-10-12	0.57	2016-11-15
2016-07-13	0.57	2016-08-15
2016-04-13	0.57	2016-05-16
2016-01-13	0.57	2016-02-16
2015-10-13	0.51	2015-11-16
2015-07-13	0.51	2015-08-14
2015-04-13	0.51	2015-05-15
2015-01-13	0.49	2015-02-13
2014-10-10	0.42	2014-11-17
2014-07-11	0.42	2014-08-15
2014-04-11	0.42	2014-05-15
2014-01-13	0.40	2014-02-14
2013-10-10	0.40	2013-11-15
2013-07-11	0.40	2013-08-15
2013-04-11	0.40	2013-05-15
2013-01-11	0.40	2013-02-15

公司名称	艾伯维公司
行业分类	制药
业务描述	艾伯维是在2013成立的，艾伯维形成了一种新的生物制药公司类企业。艾伯维将制药公司的稳定性、全球规模、资源和商业能力与生物技术的重点和文化融合在一起。艾伯维在全球的29000名员工专注于提供有利于患者的转化药物和疗法。

艾伯维公司 ABBV 深 沪

211.10

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

艾伯维公司 ABBV 深沪